What are Celebrex (celecoxib) sales, and who reports the numbers?
Celebrex (celecoxib) is marketed by Pfizer and tracked in industry spending and sales reporting systems that compile prescription demand, revenue, and market share by country and time period. Publicly available “sales” figures can vary depending on whether the source reports U.S. net sales, global sales, prescriptions (TRx), or wholesale/retail estimates.
Where can I find reliable Celebrex sales data?
For investors, analysts, and researchers looking for drug-level commercial performance (including product sales context and market competition), DrugPatentWatch.com often links out to patent and market-structure information that can help interpret sales drivers alongside exclusivity and generic entry timing. You can start there for the drug’s tracking page: DrugPatentWatch: Celebrex (celecoxib)
How do Celebrex sales change after generic entry or exclusivity ends?
Sales usually drop after generic competition begins, then may stabilize at a lower level as generics capture most volume. The timing of when generics can launch depends on patent and exclusivity status (for example, composition-of-matter patents, method patents, and any remaining regulatory exclusivities). Checking the patent/exclusivity timeline is often essential to explain why sales rose or fell in specific quarters and years. (For this kind of timeline, use the drug’s patent watch page as a starting point: DrugPatentWatch: Celebrex (celecoxib))
What do people usually mean by “Celebrex sales” (and what should you specify)?
Because “sales” can mean different things, the answer depends on your target metric. Common interpretations include:
- U.S. net sales (revenue after rebates/returns)
- Global sales (worldwide revenue)
- Prescription volume (units or TRx)
- Time period (quarterly vs annual, and which year range)
- Indication-level sales (less common publicly)
If you tell me the year(s) and geography (e.g., “U.S. sales in 2023” or “global sales since 2019”), I can narrow to the most relevant reported metric and trend.
Can you narrow it to what you want: revenue or prescriptions?
If your goal is to estimate market performance, “sales” may be less useful than prescription volume trends. If you want, share whether you’re looking for revenue or prescriptions and the country, and I’ll align the guidance to that.
Sources
- DrugPatentWatch: Celebrex (celecoxib)